Blood pressure(BP), baroreflex sensitivity (BRS), urine normetanephrine and augmentation index before and after treatment
| Subtherapeutic CPAP | Therapeutic CPAP | p-value# | |||
| Baseline | Follow-up | Baseline | Follow-up | ||
| Office mean BP mmHg | 109.3±11.7 | 107.3±11.2 | 104.2±12.6 | 102.4±8.8 | 0.81 |
| Office systolic BP mmHg | 141.6±17.4 | 140.4±17.4 | 135.8±16.0 | 133.0±12.6 | 0.46 |
| Office diastolic BP mmHg | 92.9±11.4 | 90.8±10.2 | 89.3±10.8 | 87.0±8.9 | 0.96 |
| 24-h mean BP¶ mmHg | 105.1±10.9 | 105.7±10.5 | 99.6±9.6 | 97.0±9.9 | 0.02 |
| 24-h systolic BP¶ mmHg | 138.9±20.8 | 139.5±19.2 | 131.3±13.9 | 128.5±14.0 | 0.07 |
| 24-h diastolic BP¶ mmHg | 88.3±8.1 | 88.9±8.0 | 83.9±9.3 | 81.3±9.8 | 0.04 |
| Wake mean BP mmHg | 107.9±10.9 | 110.0±10.2 | 103.2±9.2 | 100.1±10.2 | 0.002 |
| Wake systolic BP mmHg | 142.6±21.5 | 145.4±20.0 | 135.9±14.0 | 133.1±14.6 | 0.02 |
| Wake diastolic BP mmHg | 90.7±7.9 | 92.3±7.5 | 86.9±8.9 | 83.8±10.1 | 0.005 |
| Sleep mean BP mmHg | 99.3±11.8 | 98.5±9.9 | 92.0±13.1 | 89.3±11.0 | 0.35 |
| Sleep systolic BP mmHg | 131.1±21.3 | 129.8±15.9 | 121.5±17.0 | 117.4±16.8 | 0.33 |
| Sleep diastolic BP mmHg | 83.4±9.4 | 82.7±8.8 | 77.3±12.5 | 75.2±10.3 | 0.51 |
| BRS+ ms·mmHg−1 | 6.8±4.0 | 6.6±4.2 | 7.1±3.3 | 8.8±4.2 | 0.001 |
| Urine normetanephrine§ µmol·mol−1 creatinine | 158.6±64.8 | 160.9±72.3 | 179.7±80.1 | 132.7±46.5 | 0.004 |
| Augmentationƒ index % | 12.2±13.6 | 14.2±14.9 | 14.5±11.3 | 9.1±13.8 | 0.001 |
Data are presented as mean±sd, unless otherwise stated. For both groups n = 51. CPAP: continuous positive airway pressure. #: calculated by two-way ANOVA for repeated measurements and compares treatment effects; ¶: 24-h BP was measured in 33 patients in the therapeutic, and in 29 in the subtherapeutic group; +: baroreflex sensitivity was measured in 34 patients in the therapeutic, and in 43 in the subtherapeutic group; §: urine normetanephrine was measured in 51 patients in the therapeutic, and in 50 patients in the subtherapeutic group; ƒ: augmentation index was measured in 30 patients in the therapeutic, and 42 patients in the subtherapeutic group.